Celltrion, Inc. Stock Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
|
07-01 | S.Korean shares rise on robust data; battery, biopharma stocks jump | RE |
06-17 | Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug | MT |
Sales 2024 * | 3,436B 2.48B 3.4B | Sales 2025 * | 4,126B 2.98B 4.08B | Capitalization | 37,969B 27.41B 37.51B |
---|---|---|---|---|---|
Net income 2024 * | 524B 378M 518M | Net income 2025 * | 1,088B 786M 1.07B | EV / Sales 2024 * | 11.3 x |
Net Debt 2024 * | 755B 545M 746M | Net cash position 2025 * | 106B 76.56M 105M | EV / Sales 2025 * | 9.18 x |
P/E ratio 2024 * |
74.8
x | P/E ratio 2025 * |
35.8
x | Employees | - |
Yield 2024 * |
0.24% | Yield 2025 * |
0.26% | Free-Float | 66.89% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
1st Jan change | Capi. | |
---|---|---|
+15.31% | 44.44B | |
-9.61% | 37.99B | |
+37.21% | 37.75B | |
+26.97% | 30.78B | |
+12.42% | 26.17B | |
+43.39% | 14.15B | |
+33.21% | 12.59B | |
-8.02% | 11.28B | |
-14.42% | 10.47B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock